Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...
Panelists discuss how to address practical challenges in delivering chimeric antigen receptor (CAR) T cell therapy, including patient selection, bridging therapy, manufacturing delays, access barriers ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials ...
Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback